Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than comprehensive financial performance.
Material Changes
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK Ordinary share ADRs), an increase in the notional allocation of Ordinary share ADRs occurred on March 2, 2012. The transaction price was $44.23 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- The filing reports a notional increase in ADR allocations for specific directors and connected persons due to a plan re-valuation.
- Transactions involved Dr. M M Slaoui (39 ADRs), Dr. K Slaoui (25 ADRs), Mr. W C Louv (81 ADRs), and Dr. D Pulman (65 ADRs).
- The transaction price was $44.23 per ADR on March 2, 2012.
- No financial performance data is included in this specific report.